Nursing care
Ipratropium: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Ipratropium is an inhaled anticholinergic bronchodilator used mainly for COPD and combined with albuterol in acute asthma. It blocks acetylcholine at bronchial muscarinic receptors, so dry mouth is an expected effect, not a red flag. Patients with narrow-angle glaucoma must avoid letting the nebulized mist contact their eyes, since it can precipitate an acute attack.
Why this drug and not another
Ipratropium is an anticholinergic, structurally related to atropine but confined to the lungs by the inhaled route, so it blocks acetylcholine at muscarinic receptors on bronchial smooth muscle rather than stimulating beta-2 receptors the way albuterol does. That different mechanism is why it is reached for specifically in COPD, where cholinergic tone contributes more to airflow obstruction than in asthma.
It is chosen over albuterol alone in acute asthma exacerbations as an add-on, since combining a SABA with an anticholinergic gives a bronchodilator effect through two separate pathways and reduces hospital admissions more than either drug alone. Onset is slower than albuterol, around fifteen minutes, with peak effect at one to two hours, so it is not the first choice for immediate rescue on its own.
Administration and timing
Give ipratropium by metered-dose inhaler or nebulizer, typically every four to six hours for scheduled COPD management or as directed during an acute exacerbation alongside albuterol. When both are ordered together, give the albuterol first if the goal is fast symptom relief, since its quicker onset opens the airway before the slower-acting ipratropium is delivered.
Have the patient exhale fully before inhaling, then hold the breath five to ten seconds to allow deposition in the lower airways. With a nebulizer, use a mouthpiece rather than a mask when possible, since a mask increases the chance of the mist settling on the face and reaching the eyes.
Monitoring parameters
Assess breath sounds and respiratory rate before and after administration to confirm bronchodilation. Because the anticholinergic effect is largely confined to the lungs at inhaled doses, systemic monitoring is lighter than with oral anticholinergics, but still ask about urinary symptoms in men with benign prostatic hyperplasia, since even minimal systemic absorption can worsen retention.
Track how often the patient needs their combination inhaler and whether COPD symptoms are trending toward more frequent use, which can indicate disease progression rather than a dosing problem. In patients with known glaucoma, ask specifically whether they have noticed eye pain, blurred vision, or halos around lights after nebulizer treatments, since these are early signs of an angle-closure event.
Adverse effects to report
Dry mouth is expected and does not need to be reported unless it becomes severe enough to affect eating or oral comfort, at which point sips of water or sugar-free lozenges help. Report new eye pain, blurred vision, halos around lights, or a red eye immediately, since these suggest the mist has reached the eyes and triggered acute angle-closure glaucoma, which is a medical emergency.
Also report urinary retention, palpitations, or a significant increase in heart rate, all of which are less common but reflect systemic anticholinergic absorption. Paradoxical bronchospasm, where breathing worsens immediately after a dose, is rare but should stop further doses and prompt reassessment.
Contraindications and cautions
Avoid or use with caution in patients with a known allergy to atropine or its derivatives, and in those with narrow-angle glaucoma, where the mist itself is the hazard rather than the systemic dose. Use caution in men with bladder outlet obstruction or benign prostatic hyperplasia, since even inhaled anticholinergic effects can precipitate urinary retention.
There is also a documented soy or peanut allergy caution with some formulations that use soy lecithin as a propellant component, so check the product insert and the patient's allergy history before the first dose. Patients with significant cardiac arrhythmia should be used with caution given the anticholinergic effect on heart rate, though this is a smaller concern than with beta-agonists.
Teaching points the exam tests
The exam-favorite fact is the eye warning: teach the patient to use a mouthpiece rather than a face mask with the nebulizer, and to close their eyes or turn their head away if a mask must be used, because contact between the mist and the eye can trigger acute angle-closure glaucoma in a susceptible patient. This is tested precisely because it is counterintuitive for an inhaled drug to cause an eye emergency.
Reinforce that dry mouth is a normal, expected effect of the anticholinergic mechanism, not a reason to stop the drug, and that rinsing the mouth or sipping water helps. Remind the patient this is not a rescue inhaler for sudden symptoms in asthma the way albuterol is; it is scheduled or add-on therapy with a slower onset, and they should not expect the immediate relief they get from a SABA.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why does ipratropium cause dry mouth?
It is an anticholinergic drug, so it blocks muscarinic receptors that normally stimulate saliva production, not just those in the airway. Dry mouth is an expected, dose-related effect rather than a sign of a problem.
Can ipratropium cause eye problems?
Yes, if the nebulized mist contacts the eyes, particularly in a patient with narrow-angle glaucoma, where it can precipitate acute angle-closure glaucoma. Use a mouthpiece instead of a face mask and teach the patient to keep the mist away from their eyes.
Is ipratropium used for asthma or COPD?
It is used in both, but its main role is in COPD, where cholinergic bronchoconstriction is more prominent. In acute asthma it is added to albuterol rather than used alone, since combining the two mechanisms improves outcomes more than either drug by itself.
How fast does ipratropium work compared to albuterol?
It is slower, with onset around fifteen minutes and peak effect at one to two hours, compared to albuterol's onset within five to fifteen minutes. That makes it unsuitable as a standalone rescue drug for sudden bronchospasm.
More on pharmacology
Guides on this